Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01624558 |
Recruitment Status :
Withdrawn
(Measurement device not performing to standard in study environment)
First Posted : June 20, 2012
Last Update Posted : September 11, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malignant Hyperthermia | Device: In-line Carbon filter (Vapor-Clean) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient |
Study Start Date : | July 2012 |
Estimated Primary Completion Date : | June 2013 |
Estimated Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (filter in circuit)
After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
|
Device: In-line Carbon filter (Vapor-Clean)
Carbon filter placed in anesthesia breathing circuit.
Other Name: Vapor-Clean Brand Carbon Filter (Dynasthetics, LLC) |
No Intervention: No Intervention Control
After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
|
- Time to reduce Concentration of Volatile Anesthetic to <5ppm [ Time Frame: every two minutes after filter applied until concentration is <5ppm or 30 minutes ]At regular intervals (2 minutes) after application of the filters, the concentration of the volatile anesthetic will be measured. Primary outcome value will be the time to reduce breathing circuit volatile anesthetic concentration to <5ppm. If at 30 min the concentration is not <5ppm, then collection will be stopped.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 16 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy ASA PS I or II children 2 years to 16 years old
- having general anesthesia for approximately 1 hour or more
Exclusion Criteria:
- malignant hyperthermia susceptible patients (personal or family history)
- patients with known neuromuscular disorders at high risk of malignant hyperthermia (e.g., muscular dystrophy)
- egg or soy allergy
- patient or parent refusal
- pregnant patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01624558
Principal Investigator: | Robert S Greenberg, MD | Johns Hopkins University |
Responsible Party: | Robert Greenberg, MD, Associate Professor, Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT01624558 |
Other Study ID Numbers: |
NA_00049358 |
First Posted: | June 20, 2012 Key Record Dates |
Last Update Posted: | September 11, 2014 |
Last Verified: | September 2014 |
malignant hyperthermia |
Hyperthermia Fever Malignant Hyperthermia Body Temperature Changes Heat Stress Disorders |
Wounds and Injuries Intraoperative Complications Pathologic Processes Postoperative Complications |